Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026

Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026

Same author

Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities.

ERJ open research·2026

Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026

Same author

Considering molecular pharmacology for sarcoidosis treatment.

The Lancet. Respiratory medicine·2026

Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025

Search research articles

Related Experiment Video

Updated: Jul 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Fibrotic Pulmonary Sarcoidosis.

Hilario Nunes¹, Pierre-Yves Brillet², Jean-François Bernaudin³

¹AP-HP, Pulmonology Department, Avicenne Hospital, Bobigny, 93009, France; INSERM UMR 1272, Sorbonne Paris-Nord University, Bobigny, 93009, France.

Clinics in Chest Medicine

|January 20, 2024

Summary

Fibrotic pulmonary sarcoidosis (fPS) significantly impacts patient health, with outcomes varying based on fibrosis extent and complications. Understanding fPS progression is crucial for effective management and treatment strategies.

Keywords:

Fibrosis Granuloma Morbidity Mortality Progression

More Related Videos

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jul 5, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Area of Science:

Pulmonary Medicine
Rheumatology
Immunology

Background:

Fibrotic pulmonary sarcoidosis (fPS) affects approximately 20% of sarcoidosis patients.
fPS is associated with substantial morbidity and mortality.
Prognosis in fPS is highly variable, influenced by fibrosis extent, functional impairment, and pulmonary hypertension.

Purpose of the Study:

To investigate the natural history of fibrotic pulmonary sarcoidosis.
To identify risk factors for progressive, self-sustaining fibrosis.
To evaluate current management challenges and therapeutic options for fPS.

Main Methods:

Review of existing literature on fibrotic pulmonary sarcoidosis.
Analysis of patient data to assess factors influencing prognosis.
Evaluation of treatment outcomes for anti-inflammatory, rehabilitation, antifibrotic, and transplant strategies.

Main Results:

Prognosis depends on fibrosis extent, functional impairment, and pulmonary hypertension.
Acute exacerbations and infections are significant complications impacting outcomes.
The natural history, particularly the risk of progressive fibrosis, remains largely unknown.

Conclusions:

Management of fPS is complex, requiring tailored approaches.
Treatment may include anti-inflammatory drugs, rehabilitation, antifibrotic agents, or lung transplantation in select cases.
Further research is needed to understand fPS natural history and optimize therapeutic interventions.